[Antithrombotic properties of heparin independent of its anticoagulant activity]. 1994

K Krupiński, and M Bielawiec, and H K Breddin
Klinika Hematologii Akademii Medycznej w Białymstoku.

Antithrombotic effects of two glycosaminoglycans: LMWH-Fraxiparin (Sanofi) and UFH Heparinum (Polfa) have been studied in the laser-induced rat thrombosis model. The investigations were carried out on male Wistar rats. Thrombus formation was induced in small mesenteric venules 25-30 microns in diameter using argon laser. An interference contrast system based on a Leitz Orthoplan microscope was used for the evaluation of thrombus formation. The number of laser injuries needed to induce a defined thrombus proved to be a useful way to quantitate the results in this thrombosis model. Fraxiparin and UFH showed doses dependent antithrombotic effect in the laser model. Fraxiparin in minimal dose 16 aXa/kg and UFH in minimal dose 15 IU/kg 30 min after i.v. injection to the rats markedly inhibited thrombus formation in small mesenteric venules. Antithrombotic effect of the administration of minimal effective doses of both glycosaminoglycans lasted longer than 4 hours but less than 6 hours. Protamine injected in a dose 1 ml per 5000 U/heparin neutralized anticoagulant activity of both heparins in rat plasma but did not inhibit the antithrombotic effect in laser thrombosis model. After the injection of protamine antithrombotic effect of the investigated glycosaminoglycans was weaker but still observed. Further studies are needed to clarify the factors which are responsible for the antithrombotic effect of heparins after neutralization of their anticoagulant activity (inhibition factors: IIa and Xa).

UI MeSH Term Description Entries
D007834 Lasers An optical source that emits photons in a coherent beam. Light Amplification by Stimulated Emission of Radiation (LASER) is brought about using devices that transform light of varying frequencies into a single intense, nearly nondivergent beam of monochromatic radiation. Lasers operate in the infrared, visible, ultraviolet, or X-ray regions of the spectrum. Masers,Continuous Wave Lasers,Pulsed Lasers,Q-Switched Lasers,Continuous Wave Laser,Laser,Laser, Continuous Wave,Laser, Pulsed,Laser, Q-Switched,Lasers, Continuous Wave,Lasers, Pulsed,Lasers, Q-Switched,Maser,Pulsed Laser,Q Switched Lasers,Q-Switched Laser
D008297 Male Males
D011479 Protamines A group of simple proteins that yield basic amino acids on hydrolysis and that occur combined with nucleic acid in the sperm of fish. Protamines contain very few kinds of amino acids. Protamine sulfate combines with heparin to form a stable inactive complex; it is used to neutralize the anticoagulant action of heparin in the treatment of heparin overdose. (From Merck Index, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p692) Protamine,Protamine Sulfate,Protamine Chloride,Chloride, Protamine,Sulfate, Protamine
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013927 Thrombosis Formation and development of a thrombus or blood clot in BLOOD VESSELS. Atherothrombosis,Thrombus,Blood Clot,Blood Clots,Thromboses
D015912 Thrombolytic Therapy Use of infusions of FIBRINOLYTIC AGENTS to destroy or dissolve thrombi in blood vessels or bypass grafts. Fibrinolytic Therapy,Thrombolysis, Therapeutic,Therapeutic Thrombolysis,Therapy, Fibrinolytic,Therapy, Thrombolytic,Fibrinolytic Therapies,Therapeutic Thrombolyses,Therapies, Fibrinolytic,Therapies, Thrombolytic,Thrombolyses, Therapeutic,Thrombolytic Therapies

Related Publications

K Krupiński, and M Bielawiec, and H K Breddin
January 1986, Haemostasis,
K Krupiński, and M Bielawiec, and H K Breddin
January 2012, Handbook of experimental pharmacology,
K Krupiński, and M Bielawiec, and H K Breddin
October 1992, Thrombosis research,
K Krupiński, and M Bielawiec, and H K Breddin
February 1993, Journal of vascular surgery,
K Krupiński, and M Bielawiec, and H K Breddin
October 1992, The Journal of pathology,
K Krupiński, and M Bielawiec, and H K Breddin
March 2021, Immunity,
K Krupiński, and M Bielawiec, and H K Breddin
July 1965, Israel journal of medical sciences,
K Krupiński, and M Bielawiec, and H K Breddin
January 1992, Advances in experimental medicine and biology,
K Krupiński, and M Bielawiec, and H K Breddin
October 1988, Biulleten' eksperimental'noi biologii i meditsiny,
K Krupiński, and M Bielawiec, and H K Breddin
January 1980, Scandinavian journal of haematology. Supplementum,
Copied contents to your clipboard!